Leukeran (Chlorambucil)

Chlorambucil belongs to the nitrogen‑mustard class of alkylating agents. It forms covalent bonds with DNA, creating cross‑links that block DNA replication and transcription. This DNA damage leads to cell‑cycle arrest and apoptosis, especially in fast‑growing lymphoid cancer cells.

The specific dose of Leukeran is individualized by the prescribing physician based on the patient’s diagnosis, disease stage, body surface area, renal and hepatic function, and tolerance. Only a qualified healthcare professional should determine the appropriate dosing regimen.

Chlorambucil is classified as a teratogenic agent and may cause fetal harm. It is generally contraindicated during pregnancy and should be avoided while breastfeeding. Women of childbearing potential should use effective contraception throughout treatment and for a period after discontinuation as advised by their physician.

To order Leukeran, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Leukeran (chlorambucil) is an oral nitrogen‑mustard with a relatively long half‑life, allowing once‑daily dosing in many protocols. Compared with intravenous agents such as cyclophosphamide, it offers convenience of oral administration but may have a higher incidence of gastrointestinal irritation. Efficacy and safety profiles are comparable when used for approved indications.

Leukeran tablets should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture and direct sunlight, and ensure the packaging remains sealed until use. Follow standard good‑manufacturing practices when handling the medication.

Leukeran is administered orally, usually as a tablet taken with water. The exact dosing schedule—such as daily or on specific days of a treatment cycle—is determined by the treating physician based on the patient’s clinical condition and response to therapy.

The most serious risks include severe myelosuppression (leading to neutropenia, anemia, or thrombocytopenia), secondary malignancies such as acute leukemia, and serious gastrointestinal complications like ulceration or bleeding. Patients should be monitored regularly for blood‑count changes and any signs of infection or bleeding.

Leukeran should be avoided in patients with known hypersensitivity to chlorambucil or other nitrogen‑mustard agents, in those with active severe infections, and in pregnant or nursing women unless the benefits outweigh the risks. Caution is also advised for individuals with significant hepatic or renal impairment.